104 / 1851
Program
name
Lead
organization
Design Histology Indication
# Expected
to accrue
Primary
outcome
measure(s)
Clinicaltrials.
gov
identifier
SIGNATURE
Novartis
NR
ALK or ROS1
mutated solid
tumors and/or
hematologic
malignancies
Metastatic
70
CBR
NCT02186821
Solid tumors
and/or
hematologic
malignancies
with aberrations
in FGFR, PDGFR,
VEGF, cKIT, FLT3,
CSFR1, Trk, or
RET
Metastatic
80
CBR
NCT01831726
Basket trials matching patients to therapies
based on molecular profiles